We're excited to share that the FDA has approved MSHO member, Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer. https://lnkd.in/gHYa7SP4 #MSHO24
The Michigan Society of Hematology and Oncology’s Post
More Relevant Posts
-
Among participants with high-risk nonmetastatic breast cancer, daily aspirin therapy did not improve risk of breast cancer recurrence or survival in early follow-up. https://ja.ma/4bXSD4K
-
-
✞ | Husband | Father | CEO | Activist | Founder | Almsgiver | Builder | Professor
Together, we can make a real impact in the fight against #ColorectalCancer (CRC). Join us by urging leaders to help us change this projection below well before 2030: https://lnkd.in/gA6d7Tt9 Let's #PrioritizeCRC & work towards a brighter, healthier future for all. #NeverTooYoung h/t Fight Colorectal Cancer
-
-
WATCH NOW! 👉Immunotherapy and its impact on overall survival in patients with recurrent endometrial cancer Drs. Powell and Naumann discuss SGO late-breaking abstract: Overall survival in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY https://lnkd.in/gTQDnBRx
-
-
A panel of medical oncologists discuss got together to provide updates in bladder cancer and provide comprehensive insights on the evolving treatment landscape following ASCO #GU2024. #oncology https://lnkd.in/eBhjBhZZ
-
Imagio® has tangible benefits for everyone involved in breast cancer diagnostics, whether it’s overburdened staff or practices trying to boost their efficiency. See how it can improve the care pathway for you at https://lnkd.in/ga-DiWyA #BreastCancer #optoacoustic #ImagioImaging
-
-
Passionate Medical Oncologist | Assistant Lecturer at National Cancer Institute | ESMO Certified | ESCO Graduate |ESGO member| ASCO Member | Dedicated to Improving Patient QOL and Outcomes.
1st ADC in ovarian cancer
Mirvetuximab soravtansine monotherapy led to an objective response rate of 51.9% in heavily pretreated patients with FRα+, platinum-sensitive ovarian cancer, meeting the primary end point of the phase 2 PICCOLO trial. #GYNCSM https://lnkd.in/eJtiWjfe
Phase 2 Study of Mirvetuximab in Ovarian Cancer Meets Primary End Point
-
Focusing on HER2+ breast cancer
Focusing on HER2+ breast cancer, Erika P. Hamilton, MD, and the Oncology Brothers review data from JBCRG-M06/EMERALD looking at trastuzumab and pertuzumab in combination with eribulin or a taxane in locally advanced or metastatic disease. #BCSM #ASCO24 https://lnkd.in/eXsdHsD3
Recent Data from JBCRG-M06/EMERALD in HER2+ Breast Cancer
targetedonc.com
-
Explore strategies with our On-Demand Video featuring breast cancer experts | Adjuvant Endocrine Therapy in HR+ Breast Cancer: Enhancing Quality Care and Patient Outcomes | 0.5-hour CME/CE | #MedEd #cme #HR+breastcancer | https://bit.ly/495OtG3
-
-
Explore strategies with our On-Demand Video featuring breast cancer experts | Adjuvant Endocrine Therapy in HR+ Breast Cancer: Enhancing Quality Care and Patient Outcomes | 0.5-hour CME/CE | #MedEd #cme #HR+breastcancer | https://bit.ly/495OtG3
-
-
Understanding breast cancer stages and the key to breast cancer treatment: by Chinwe Godwin-Omoaka, FICMC Stay informed! Stay breast aware! Early detection saves lives #breastcancerawareness #stayinformed #earlydetection #worthywellnessinitiative
Field Reimbursement Manager| Account Manager| Market Access Specialist |Specialty Pharmacy| Buy and Bill| Pharmacy Medical Benefit Access Reimbursement| Medicare Part B&D Access.
2moLove this